Virology Journal is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.
Call for papers
- Viruses across borders
- World Aids Day
- Food security and sustainability from a microbiology perspective
- Coronaviruses: emerging and re-emerging pathogens in humans and animals
A cross journal collection that will cover various aspects of maintaining or enhancing food production, sustainability and security from a microbiology perspective.
Currently open for submissions - Submit Here
This thematic series emphasizes advances and key discoveries in the animal origin, viral evolution, epidemiology, diagnostics and pathogenesis of different emerging and re-emerging coronaviruses. Currently open for submissions - Submit Here
Edited by Susanna K. P. Lau, Hayes Luk, Siddharth Sridhar, and Linfa Wang
Sign up to receive article alerts
Find a selection of articles published across Springer Nature, as well as additional commentary and books relevant to SARS-CoV-2 and COVID-19 research.
Discover all the article collections published in Virology Journal. Find out more.
Aims and scope
Virology Journal is an open access, peer reviewed journal that considers articles on all aspects of virology, including research on the viruses of animals, plants and microbes. The journal welcomes basic research as well as pre-clinical and clinical studies of novel diagnostic tools, vaccines and anti-viral therapies.
Why publish your article in Virology Journal?
- Edited by leading virologists, our journal brings together all areas of virology research.
- With more than 100,000 monthly accesses, we ensure exceptional visibility and community attention for your work.
- We welcome basic research, as well as pre-clinical and clinical studies, and research on vaccines and anti-viral therapies.
- We deliver high levels of author satisfaction, with 93% of our published authors reporting that they would definitely or probably publish with us again.
Clinical Virology: Fred Kibenge, University of Prince Edward Island, Canada
Emerging viruses: Tom Geisbert, University of Texas Medical Branch, USA
Hepatitis viruses: Wan-Long Chuang, Kaohsiung Medical University, Taiwan
Herpes viruses: Tony Cunningham, The Westmead Institute for Medical Research, Australia
Influenza viruses: Hualan Chen, Chinese Academy of Agricultural Sciences, China
Negative-strand RNA viruses: John Barr, University of Leeds, United Kingdom
Other viruses: Erna Geessien Kroon, Universidade Federal de Minas Gerais, Brazil
Plant viruses: Chikara Masuta, Hokkaido University, Japan
Positive-strand RNA viruses: Jason Mackenzie, The University of Melbourne, Australia
Retroviruses: Linda Chelico, University of Saskatchewan, Canada
Veterinary DNA viruses: Gerlinde Van de Walle, Cornell University, USA
Viruses of microbes: Joana Azeredo, University of Minho, Portugal
Announcing the launch of In Review
Virology Journal, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Alan McLachlan, Co-Editor-in-Chief
Alan McLachlan is a molecular geneticist and hepadnavirologist. He currently serves as a Professor in the Department of Microbiology and Immunology, University of Illinois Chicago, USA. His interests are focused on hepatitis viruses, primarily on hepatitis B virus (HBV) and its relationships to liver physiology. His research is currently directed toward understanding the relationships between HBV transcription and viral biosynthesis using both cell culture and animal models. His long-term goals include the identification of cellular gene products as targets for the development of small molecular weight antiviral compounds which, in combination with current nuceot(s)ide analog therapeutics, will resolve chronic HBV infections.
Leo Poon, Co-Editor-in-Chief
Leo Poon is a molecular virologist. He currently serves as a Professor in the School of Public Health, The University of Hong Kong and as a co-director of HKU-Pasteur Research Pole. He has strong interests in emerging viruses, including coronavirus and influenza virus. He researches on different aspects of these viruses, ranging from basic virology to clinical diagnosis. His ultimate goal is to use scientific findings to inform public health policy. Over the years, he has published about 290 peer-reviewed articles. Thus far, his work has been cited over 41,000 times and he has an H-index of 95 (Web of Science).
Annual Journal Metrics
2022 Citation Impact
4.8 - 2-year Impact Factor
3.9 - 5-year Impact Factor
1.006 - SNIP (Source Normalized Impact per Paper)
1.092 - SJR (SCImago Journal Rank)
10 days submission to first editorial decision for all manuscripts (Median)
120 days submission to accept (Median)
150,828 Altmetric mentions